Immune checkpoint blockade (ICB) has revolutionized modern cancer therapy, arousing
great interest in the neuro-oncology community. While several reports show that subsets of …

Glioblastoma is the most aggressive primary brain tumor with a poor prognosis. The 2021
WHO CNS5 classification has further stressed the importance of molecular signatures in …

The large diversity of central nervous system (CNS) tumor types in children and adolescents
results in disparate patient outcomes and renders accurate diagnosis challenging. In this …

Up to 30% of colorectal, endometrial and gastric cancers have a deficiency in mismatch
repair (MMR) protein expression due to either germline or epigenetic inactivation. Patients …

Immune checkpoint inhibition (ICI) is effective for replication-repair-deficient, high-grade
gliomas (RRD-HGG). The clinical/biological impact of immune-directed approaches after …

The role of immune checkpoint inhibitors (ICIs) in the treatment of pediatric cancers
continues to evolve. Such therapies function by augmenting existing antitumor T-cell …

Background Therapeutic options are limited in pediatric CNS malignancies. CheckMate 908
(NCT03130959) is an open-label, sequential-arm, phase 1b/2 study investigating nivolumab …

Glioblastoma is a clinically and molecularly heterogeneous disease, and new predictive
biomarkers are needed to identify those patients most likely to respond to specific …

Background We investigated the utility of a molecular classifier tool and genetic alterations
for predicting prognosis in Japanese patients with endometrial cancer. Methods A total of …

Background Germline variants affecting the proofreading activity of polymerases epsilon and
delta cause a hereditary cancer and adenomatous polyposis syndrome characterized by …